Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder
NCT ID: NCT00151450
Last Updated: 2021-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
390 participants
INTERVENTIONAL
2005-03-31
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR
NCT00183274
Combined Treatment for Generalized Anxiety Disorder (GAD)
NCT00620776
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
NCT00195598
Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder
NCT07330648
Study Evaluating Venlafaxine ER in Patients With Panic Disorder
NCT00044772
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
Venlafaxine XR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Current diagnosis of depression, dysthymia, obsessive-compulsive disorder.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
De Pinte, , Belgium
Pfizer Investigational Site
Ghent, , Belgium
Pfizer Investigational Site
Waregem, , Belgium
Pfizer Investigational Site
Kelowna, British Columbia, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Gatineau, Quebec, Canada
Pfizer Investigational Site
Saint-Jean-sur-Richelieu, Quebec, Canada
Pfizer Investigational Site
Angoulême, , France
Pfizer Investigational Site
Arcachon, , France
Pfizer Investigational Site
Bully-les-Mines, , France
Pfizer Investigational Site
Cherbourg, , France
Pfizer Investigational Site
Élancourt, , France
Pfizer Investigational Site
Orvault, , France
Pfizer Investigational Site
Rennes, , France
Pfizer Investigational Site
Saint-André-de-Cubzac, , France
Pfizer Investigational Site
Savigny-sur-Orge, , France
Pfizer Investigational Site
Strasbourg, , France
Pfizer Investigational Site
Versailles, , France
Pfizer Investigational Site
Bray, County Wicklow, Ireland
Pfizer Investigational Site
Vicenza, Bassano DEL Grappa, Italy
Pfizer Investigational Site
Città di Castello, Perugia, Italy
Pfizer Investigational Site
Catania, , Italy
Pfizer Investigational Site
Sassari, , Italy
Pfizer Investigational Site
Wildervank, Provincie Groningen, Netherlands
Pfizer Investigational Site
Hoogvliet, , Netherlands
Pfizer Investigational Site
Huizen, , Netherlands
Pfizer Investigational Site
Losser, , Netherlands
Pfizer Investigational Site
Musselkanaal, , Netherlands
Pfizer Investigational Site
Oude Pekela, , Netherlands
Pfizer Investigational Site
Vic, Barcelona, Spain
Pfizer Investigational Site
Alcalá de Henares, Madrid, Spain
Pfizer Investigational Site
Langreo, Principality of Asturias, Spain
Pfizer Investigational Site
Gandia, Valencia, Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Salamanca, , Spain
Pfizer Investigational Site
Zamora, , Spain
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Linköping, , Sweden
Pfizer Investigational Site
Lund, , Sweden
Pfizer Investigational Site
Malmo, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Sundsvall, , Sweden
Pfizer Investigational Site
Trollhättan, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009 Mar;24(2):87-96. doi: 10.1097/yic.0b013e32831d7980.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0081012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.